Eupraxia Pharmaceuticals Inc. Common Stock (EPRX)

Price$7.20

Favorite Metrics

Price vs S&P 500 (26W)7.21%

Price vs S&P 500 (4W)-10.00%

Market Capitalization$604.58M

All Metrics

Book Value / Share (Quarterly)$1.58

P/TBV (Annual)11.17x

Indicated Dividend (Annual)$0.00

Cash Flow / Share (Quarterly)$-0.56

Price vs S&P 500 (YTD)-8.99%

EPS (TTM)$-0.93

10-Day Avg Trading Volume0.05M

EPS Excl Extra (TTM)$-0.93

EPS (Annual)$-0.97

ROI (Annual)-47.02%

Cash / Share (Quarterly)$1.55

ROA (Last FY)-44.78%

EBITD / Share (TTM)$-0.96

ROE (5Y Avg)-338.07%

Cash Flow / Share (Annual)$-0.56

P/B Ratio5.38x

P/B Ratio (Quarterly)4.69x

Net Income / Employee (Annual)$-1

Net Interest Coverage (TTM)-256.31x

ROA (TTM)-66.70%

EPS Incl Extra (Annual)$-0.97

Current Ratio (Annual)15.12x

Quick Ratio (Quarterly)14.43x

3-Month Avg Trading Volume0.08M

52-Week Price Return119.37%

Revenue / Employee (TTM)$0

Tangible BV / Share (Quarterly)$0.63

52-Week High$12.86

EPS Excl Extra (Annual)$-0.97

CapEx CAGR (5Y)59.81%

Tangible BV CAGR (5Y)16.55%

26-Week Price Return15.95%

Quick Ratio (Annual)14.43x

13-Week Price Return-21.45%

Total Debt / Equity (Annual)0.00x

Current Ratio (Quarterly)15.12x

Enterprise Value$360.959

Book Value / Share Growth (5Y)5.08%

Revenue / Employee (Annual)$0

Cash / Share (Annual)$1.55

3-Month Return Std Dev52.03%

Net Income / Employee (TTM)$-1

ROE (Last FY)-47.02%

Net Interest Coverage (Annual)-23.86x

EPS Basic Excl Extra (Annual)$-0.97

Total Debt / Equity (Quarterly)0.00x

EPS Incl Extra (TTM)$-0.93

ROI (TTM)-69.12%

Revenue / Share (Annual)$0.00

Tangible BV / Share (Annual)$0.60

Price vs S&P 500 (52W)84.27%

Year-to-Date Return-5.62%

5-Day Price Return-1.42%

EPS Normalized (Annual)$-0.97

ROA (5Y Avg)-84.11%

Month-to-Date Return-2.99%

Cash Flow / Share (TTM)$-1.44

EBITD / Share (Annual)$-0.96

LT Debt / Equity (Annual)0.00x

ROI (5Y Avg)-104.64%

LT Debt / Equity (Quarterly)0.00x

EPS Basic Excl Extra (TTM)$-0.93

P/TBV (Quarterly)8.43x

P/B Ratio (Annual)4.69x

Book Value / Share (Annual)$1.58

Price vs S&P 500 (13W)-24.32%

Beta1.44x

Revenue / Share (TTM)$0.00

ROE (TTM)-69.12%

52-Week Low$4.38

Analyst Recommendations

Jan 2026

Feb 2026

Mar 2026

Apr 2026

4.13

4.11

4.27

About

Eupraxia Pharmaceuticals is a clinical-stage biotech company developing extended-release, locally delivered therapeutics using its proprietary Diffusphere technology. Its lead candidate, EP-104, targets osteoarthritis and eosinophilic esophagitis, addressing unmet medical needs through improved drug delivery profiles.